Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 févr. 2024 16h01 HE
|
Vaxcyte, Inc.
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult...
Vaccine Collaboration and Licensing Deals Report: A Comprehensive Analysis of Biopharma Industry Agreements from 2016-2023
23 févr. 2024 04h13 HE
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Vaccine Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering. The Biopharma sector witnesses a...
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20 févr. 2024 07h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
15 févr. 2024 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Growing Applications in Pharmaceutical and Food and Beverage Industries to Surge Chromatography Instrumentation Market at 5.6% CAGR by 2034 | Future Market Insights, Inc.
09 févr. 2024 08h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to Future Market Insights (FMI), the global chromatography instrumentation market is expected to grow from US$ 10.3 billion in 2024 to US$...
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
02 févr. 2024 18h39 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
01 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Global Influenza Vaccine Market Analysis & Forecast Report 2024: Advanced R&D Initiatives Poised to Catalyze Growth Through 2034
31 janv. 2024 09h18 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market Analysis & Forecast 2024-2034: Market By Vaccine Type; By Indication; By Age Group; By Route of Administration; By...
Veteran ABC News Correspondent John Quiñones to Speak at The Immunization Partnership 2024 Annual Dinner
31 janv. 2024 08h55 HE
|
The Immunization Partnership
HOUSTON, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The Immunization Partnership (TIP), a statewide nonprofit committed to a healthy Texas, is proud to welcome San Antonio native and award-winning ABC...
Vaxcyte Announces Pricing of $750 Million Public Offering
30 janv. 2024 23h37 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...